New drug duo takes on tough cancers: hope for advanced bladder, kidney, and melanoma patients
NCT ID NCT05661955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already tried at least one prior treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Jining No1 Peoples Hospital West Branch
Jining, Shandong, 272000, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Hospital and Clinical Medical School, Lanzhou University
Lanzhou, Gansu, 730030, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Can we predict who needs extra therapy after kidney cancer surgery?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?